4-Aza-3-hydroxymethyl-3-methyl-1-oxaspiro[4.5]decane | 69184-33-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氮杂螺癸烷衍生物
• 英文名称: 4-Aza-3-hydroxymethyl-3-methyl-1-oxaspiro[4.5]decane
• 英文别名: 2-Spirocyclohexyl-4-methyl-4-hydroxymethyl-1,3-oxazolidine；(3-Methyl-1-oxa-4-aza-spiro[4.5]dec-3-yl)-methanol；4-Aza-3-hydroxymethyl-3-methyl-1-oxaspiro[4,5]decane；(3-methyl-1-oxa-4-azaspiro[4.5]dec-3-yl)methanol；(3-Methyl-1-oxa-4-azaspiro[4.5]decan-3-yl)methanol
• CAS: 69184-33-4
• 化学式: C₁₀H₁₉NO₂
• 分子量: 185.266
• InChiKey: CKCZKCYXNIUSKF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  41.5
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-Aza-3-hydroxymethyl-3-methyl-1-oxaspiro[4.5]decane 生成 4-aza-3-methoxymethyl-3-methyl-1-oxaspiro[4.5]decane
  参考文献：
  名称：

  BAIR, KENNETH W.

  摘要：

  DOI：
• 作为产物：
  描述：

  环己酮 、 2-氨基-2-甲基-1,3-丙二醇 在 对甲苯磺酸 作用下， 以 苯 为溶剂， 反应 12.0h， 以71%的产率得到4-Aza-3-hydroxymethyl-3-methyl-1-oxaspiro[4.5]decane
  参考文献：
  名称：

  基于TRIS（α，α，α-三羟甲基氨基甲烷）和相关的氨基多元醇骨架的一些1，3-氧唑烷体系的合成和立体化学。第2部分：1-Aza-3,7-二氧杂双环[3.3.0]辛烷

  摘要：

  显示TRIS与等量的两种羰基化合物的反应非对映选择性地提供标题化合物。结果作为合成策略进行了讨论，并且立体化学得到理论计算和高分辨率NMR数据的支持。

  DOI：

  10.1016/s0040-4020(00)00264-7

文献信息

• Fluoranthene derivatives
  申请人：Burroughs Wellcome Co.

  公开号：US04720587A1

  公开（公告）日：1988-01-19

  The present invention relates to compounds of formula (I) ArCH.sub.2 R.sup.1 (I) or a monomethyl or a monoethyl ether thereof (the compound of formula (I) including these ethers may contain no more than 30 carbon atoms in total); ethers, esters thereof; acid addition salts thereof; wherein Ar is a fluoranthene or substituted fluoranthene ring system; R.sup.1 contains not more than eight carbon carbon atoms and is a group ##STR1## wherein m is 0 or 1; R.sup.5 is hydrogen; R.sup.6 and R.sup.7 are the same or different and each is hydrogen or C.sub.1-3 alkyl optionally substituted by hydroxy; R.sup.8 and R.sup.9 are the same or different and each is hydrogen or C.sub.1-3 alkyl; ##STR2## is a five- or six-membered saturated carbocyclic ring; R.sup.10 is hydrogen, methyl or hydroxymethyl; R.sup.11, R.sup.12 and R.sup.13 are the same or different and each is hydrogen or methyl; R.sup.14 is hydrogen, methyl, hydroxy, or hydroxymethyl.

  本发明涉及化合物的公式（I）ArCH.sub.2 R.sup.1（I）或其单甲基或单乙基醚（公式（I）的化合物包括这些醚，在总共不超过30个碳原子）；醚，酯；酸盐；其中Ar是氟蒽或取代的氟蒽环系统；R.sup.1含有不超过八个碳原子，并且是一个基团##STR1##其中m为0或1；R.sup.5为氢；R.sup.6和R.sup.7相同或不同，每个是氢或C.sub.1-3烷基，可选择地被羟基取代；R.sup.8和R.sup.9相同或不同，每个是氢或C.sub.1-3烷基；##STR2##是一个五元或六元饱和碳环；R.sup.10为氢，甲基或羟甲基；R.sup.11，R.sup.12和R.sup.13相同或不同，每个是氢或甲基；R.sup.14为氢，甲基，羟基或羟甲基。
• Anthracene derivatives
  申请人：Burroughs Wellcome Co.

  公开号：US04719049A1

  公开（公告）日：1988-01-12

  The present invention relates to compounds of formula (I) ArCH.sub.2 R.sup.1 (I) or a monomethyl or a monoethyl ether thereof (the compound of formula (I) including these ethers may contain no more than 30 carbon atoms in total); ethers, esters thereof; acid addition salts thereof; wherein Ar is an anthracene or substituted anthracene ring system; R.sup.1 contains not more than eight carbon carbon atoms and is a group ##STR1## wherein m is 0 or 1; R.sup.5 is hydrogen; R.sup.6 and R.sup.7 are the same or different and each is hydrogen or C.sub.1-3 alkyl optionally substituted by hydroxy; R.sup.8 and R.sup.9 are the same or different and each is hydrogen or C.sub.1-3 alkyl; --C--C-- is a five- or six-membered saturated carbocyclic ring; R.sup.10 is hydrogen, methyl or hydroxymethyl; R.sup.11, R.sup.12 and R.sup.13 are the same or different and each is hydrogen or methyl; R.sup.14 is hydrogen, methyl, hydroxy, or hydroxymethyl.

  本发明涉及通式(I)ArCH.sub.2 R.sup.1 (I)的化合物或其单甲基或单乙基醚(通式(I)的化合物包括这些醚，总共含有不超过30个碳原子);其醚、酯;其酸加成盐;其中Ar为蒽或取代蒽环系;R.sup.1含有不超过八个碳碳原子，为如下基团##STR1##其中m为0或1;R.sup.5为氢;R.sup.6和R.sup.7相同或不同，各自为氢或C.sub.1-3烷基，可选择性地被羟基取代;R.sup.8和R.sup.9相同或不同，各自为氢或C.sub.1-3烷基;--C--C--为五元或六元饱和碳环;R.sup.10为氢、甲基或羟甲基;R.sup.11、R.sup.12和R.sup.13相同或不同，各自为氢或甲基;R.sup.14为氢、甲基、羟基或羟甲基。
• Crysene compound
  申请人：Burroughs Wellcome Co.

  公开号：US04719048A1

  公开（公告）日：1988-01-12

  The present invention relates to compounds of formula (I) ArCH.sub.2 R.sup.1 (I) or a monomethyl or a monoethyl ether thereof (the compound of formula (I) including these ethers may contain no more than 30 carbon atoms in total); ethers, esters thereof; acid addition salts thereof; wherein Ar is a chrysene or substituted chrysene ring system; R.sup.1 contains not more than eight carbon atoms and is a group ##STR1## wherein m is 0 or 1; R.sup.5 is hydrogen; R.sup.6 and R.sup.7 are the same or different and each is hydrogen or C.sub.1-3 alkyl optionally substituted by hydroxy; R.sup.8 and R.sup.9 are the ame or different and each is hydrogen or C.sub.1-3 alkyl; ##STR2## is a five- or six-membered saturated carbocyclic ring; R.sup.10 is hydrogen, methyl or hydroxymethyl; R.sup.11, R.sup.12 and R.sup.13 are the same or different and each is hydrogen or methyl; R.sup.14 is hydrogen, methyl, hydroxy, or hydroxymethyl.

  本发明涉及通式(I)ArCH₂R¹(I)的化合物或其单甲基或单乙基醚(通式(I)的化合物包括这些醚，其总共含有不超过30个碳原子); 醚、酯及其酸加成盐; 其中Ar是晕苯或取代晕苯环系; R¹含有不超过八个碳原子，是如下所示的基团##STR1##其中m是0或1; R⁵是氢; R⁶和R⁷相同或不同，各自是氢或C₁-₃烷基，可选择性地被羟基取代; R⁸和R⁹相同或不同，各自是氢或C₁-₃烷基; ##STR2##是一个五元或六元饱和碳环; R¹⁰是氢、甲基或羟甲基; R¹¹、R¹²和R¹³相同或不同，各自是氢或甲基; R¹⁴是氢、甲基、羟基或羟甲基。
• Perylene derivatives
  申请人：Burroughs Wellcome Co.

  公开号：US04719236A1

  公开（公告）日：1988-01-12

  The present invention relates to compounds of formula (I) ArCH.sub.2 R.sup.1 (I) or a monomethyl or a monoethyl ether thereof (the compound of formula (I) including these ethers may contain no more than 30 carbon atoms in total); ethers, esters thereof; acid additon salts thereof; wherein Ar is a perylene or substituted perylene ring system; R.sup.1 contains not more than eight carbon carbon atoms and is a group ##STR1## wherein m is 0 or 1; R.sup.5 is hydrogen; R.sup.6 and R.sup.7 are the same or different and each is hydrogen or C.sub.1-3 alkyl optionally substituted by hydroxy; R.sup.8 and R.sup.9 are the same or different and each is hydrogen or C.sub.1-3 alkyl; ##STR2## is a five- or six-membered saturated carbocyclic ring; R.sup.10 is hydrogen, methyl or hydroxymethyl; R.sup.11, R.sup.12 and R.sup.13 are the same or different and each is hydrogen or methyl; R.sup.14 is hydrogen, methyl, hydroxy, or hydroxymethyl.

  本发明涉及通式(I)ArCH2R1(I)的化合物或其单甲基或单乙基醚(通式(I)的化合物包括这些醚，可能总共含有不超过30个碳原子);其醚、酯;其酸加成盐;其中Ar是芤或取代的芤环系;R1包含不超过八个碳碳原子，并且是如下所示的基团##STR1##其中m为0或1;R5为氢;R6和R7相同或不同，各自为氢或C1-3烷基，可选地被羟基取代;R8和R9相同或不同，各自为氢或C1-3烷基;##STR2##是五元或六元饱和碳环;R10为氢、甲基或羟甲基;R11、R12和R13相同或不同，各自为氢或甲基;R14为氢、甲基、羟基或羟甲基。
• Crysene derivatives
  申请人：Burroughs Wellcome Co.

  公开号：US04719046A1

  公开（公告）日：1988-01-12

  The present invention relates to compounds of formula (I) ArCH.sub.2 R.sup.1 (I) or a monomethyl or a monoethyl ether thereof (the compound of formula (I) including these ethers may contain no more than 30 carbon atoms in total); ethers, esters thereof; acid addition salts thereof; wherein Ar is a chrysene or substituted chrysene ring system; R.sup.1 contains not more than eight carbon atoms and is a group ##STR1## wherein m is 0 or 1; R.sup.5 is hydrogen; R.sup.6 and R.sup.7 are the same or different and each is hydrogen or C.sub.1-3 alkyl optionally substituted by hydroxy; R.sup.8 and R.sup.9 are the same or different and each is hydrogen or C.sub.1-3 alkyl, ##STR2## is a five- or six-membered saturated carbocyclic ring; R.sup.10 is hydrogen, methyl or hydroxymethyl; R.sup.11, R.sup.12 and R.sup.13 are the same or different and each is hydrogen or methyl; R.sup.14 is hydrogen, methyl, hydroxy, or hydroxymethyl.

  本发明涉及式(I)ArCH.sub.2 R.sup.1(I)的化合物或其单甲基或单乙基醚(式(I)化合物包括这些醚，可能总共含有不超过30个碳原子);其醚、酯;其酸加成盐;其中Ar是晕苯或取代晕苯环系;R.sup.1包含不超过八个碳原子，并且是如下所示的基团##STR1##其中m是0或1;R.sup.5是氢;R.sup.6和R.sup.7相同或不同，各自为氢或C.sub.1-3烷基，任选被羟基取代;R.sup.8和R.sup.9相同或不同，各自为氢或C.sub.1-3烷基，##STR2##是五元或六元饱和碳环;R.sup.10是氢、甲基或羟甲基;R.sup.11、R.sup.12和R.sup.13相同或不同，各自为氢或甲基;R.sup.14是氢、甲基、羟基或羟甲基。